Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sanofi has launched a Phase 3 clinical study titled A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy. The study aims to test the efficacy and safety of riliprubart compared to the standard IVIg treatment in adults with CIDP, a condition requiring ongoing maintenance therapy. This research is significant as it explores a potentially more effective treatment option for CIDP patients.
The study tests riliprubart, an experimental drug, against the standard IVIg treatment. Riliprubart is administered as an intravenous solution, and the study includes a placebo component to ensure accurate results.
This interventional study follows a randomized, parallel assignment model with a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on August 21, 2024, with an estimated completion timeline of 109 weeks, including screening, treatment, and follow-up phases. The last update was submitted on June 30, 2025, indicating that the study is actively recruiting participants.
The outcome of this study could significantly impact Sanofi’s market position, potentially boosting investor confidence if riliprubart proves to be a superior treatment. This development is particularly relevant in the competitive pharmaceutical industry, where advancements in treatment options can influence stock performance and investor sentiment.
The study is ongoing, and further details are available on the ClinicalTrials portal.